Erin Lockard, MD
Hospitalist · Philadelphia, PANPI 1881789253
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 25.8% of the total. Among hospitalist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$994
- Lilly USA, LLC$456
- Novo Nordisk$365
- Amgen$289
- Pfizer$259
- Eisai Inc.$140
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,849100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $994 |
| Lilly USA, LLC | 27 | $456 |
| Novo Nordisk | 22 | $365 |
| Amgen | 18 | $289 |
| Pfizer | 17 | $259 |
| Eisai Inc. | 7 | $140 |
| Boehringer Ingelheim | 6 | $114 |
| Radius Health, Inc. | 4 | $97 |
| Sumitomo Pharma America, Inc. | 6 | $94 |
| Astellas Pharma US Inc | 4 | $81 |
| AstraZeneca | 6 | $79 |
| Nevro Corp. | 4 | $74 |
| Johnson & Johnson | 5 | $74 |
| Amarin Pharma, Inc. | 5 | $73 |
| Boston Scientific | 3 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| GSK | 4 | $59 |
| Exact Sciences | 4 | $57 |
| Bayer | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Dexcom, Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Spinal Simplicity, LLC | 1 | $24 |
| Globus Medical | 1 | $23 |
| Ardelyx, Inc. | 1 | $23 |
| Vital Connect, Inc | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Merck | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Paratek Pharmaceuticals, Inc. | 1 | $11 |
| Endogastric Solutions, Inc | 2 | $7 |
How this compares
$3,849 in reported general payments places this provider in the 95th percentile of 1,287 hospitalist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $91,038 |
| EliquisApixaban | 62 | $68,541 |
| JanuviaSitagliptin Phosphate | 38 | $45,274 |
| JardianceEmpagliflozin | 38 | $39,581 |
| XareltoRivaroxaban | 31 | $35,936 |
| TrulicityDulaglutide | 21 | $22,702 |
| MyrbetriqMirabegron | 14 | $19,511 |
| MounjaroTirzepatide | 16 | $15,692 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $11,842 |
| Atorvastatin Calcium | 729 | $5,829 |
| SynthroidLevothyroxine Sodium | 94 | $5,822 |
| Levothyroxine Sodium | 597 | $5,652 |
| Duloxetine Hcl | 88 | $4,113 |
| Gabapentin | 189 | $4,105 |
| Pantoprazole Sodium | 288 | $3,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $365 | $91,03880 claims |
| PfizerEliquis | $259 | $68,54162 claims |
| MerckJanuvia | $14 | $45,27438 claims |
| Boehringer IngelheimJardiance | $114 | $39,58138 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $456 | $38,39437 claims |
| Johnson & JohnsonXarelto | $74 | $35,93631 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $19,51114 claims |
| GSKBreo Ellipta | $59 | $11,84222 claims |
| AbbVieSynthroid | $994 | $5,82294 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $5,652597 claims |
| AstraZenecaSymbicort | $79 | $2,90911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,287 hospitalist providers in Pennsylvania.
Other hospitalist in Philadelphia
- Khalid AhmedPhiladelphia$55K
- Irfan AhsanPhiladelphia$21K
- Kevin VolppPhiladelphia$17K
- Matthew DemczkoPhiladelphia$11K
- Carmen GuerraPhiladelphia$7K
- Victor CottonPhiladelphia$5K
- Michael TaddonioPhiladelphia$4K
- Carli PetersPhiladelphia$3K
- Umang PatelLanghorne$21K
- Amanulla KhajiWynnewood$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.